Switch theme
Sign up to access all valuation multiples
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate pain with carers. It operates in one segment namely sale of its pain assessment solutions.
2010
n/a
Last FY Revenue $1.7M
Last FY EBITDA -$6.1M
$62.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Painchek achieved revenue of $1.7M and an EBITDA of -$6.1M.
Painchek expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Painchek valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.7M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 27% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -357% | XXX | XXX | XXX |
| EBIT | XXX | -$6.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -358% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.3M | XXX | XXX | XXX |
| Net Margin | XXX | -312% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Painchek's stock price is AUD 0 (or $0).
Painchek has current market cap of AUD 99.5M (or $63.9M), and EV of AUD 96.6M (or $62.0M).
See Painchek trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62.0M | $63.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Painchek has market cap of $63.9M and EV of $62.0M.
Painchek's trades at 41.9x EV/Revenue multiple, and -10.6x EV/EBITDA.
Equity research analysts estimate Painchek's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Painchek's P/E ratio is not available.
See valuation multiples for Painchek and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63.9M | XXX | $63.9M | XXX | XXX | XXX |
| EV (current) | $62.0M | XXX | $62.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 41.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -10.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -12.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPainchek's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Painchek's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Painchek's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Painchek and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 77% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 172% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 385% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Painchek acquired XXX companies to date.
Last acquisition by Painchek was XXXXXXXX, XXXXX XXXXX XXXXXX . Painchek acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Painchek founded? | Painchek was founded in 2010. |
| Where is Painchek headquartered? | Painchek is headquartered in Australia. |
| Is Painchek publicy listed? | Yes, Painchek is a public company listed on ASX. |
| What is the stock symbol of Painchek? | Painchek trades under PCK ticker. |
| When did Painchek go public? | Painchek went public in 2012. |
| Who are competitors of Painchek? | Similar companies to Painchek include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Painchek? | Painchek's current market cap is $63.9M |
| Is Painchek profitable? | Yes, Painchek is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
